Akero’s 96-Week Fibrosis Data Sparkle In MASH
Akero’s Phase IIb study of FGF21 analog efruxifermin demonstrates long-term reduction or resolution of fibrosis, but concerns about bone mineral density declines may confound the data.
Akero’s Phase IIb study of FGF21 analog efruxifermin demonstrates long-term reduction or resolution of fibrosis, but concerns about bone mineral density declines may confound the data.